Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026
Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
Clinical Data BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication pharminent May 21, 2026
Clinical Data ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD pharminent May 21, 2026
Clinical Data ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis pharminent May 21, 2026
Clinical Data Beam one-ups Wave as both show promise of genetic editing for AATD pharminent May 20, 2026
Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis pharminent May 20, 2026
Clinical Data Relay doubles the bar, outpacing Novartis with a 60% response in rare disease pharminent May 19, 2026
Clinical Data Relay drug shows early promise against rare blood vessel diseases pharminent May 19, 2026
Clinical Data BioMarin suffers another blow to rare disease portfolio in Phase 3 flop pharminent May 19, 2026
Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis pharminent May 19, 2026
Clinical Data Merck ADC, licensed from China, hits mark in first big global trial pharminent May 18, 2026
Clinical Data Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate pharminent May 15, 2026
Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term pharminent May 15, 2026
Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results pharminent May 14, 2026
Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition pharminent May 13, 2026
Clinical Data Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching pharminent May 13, 2026
Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial pharminent May 13, 2026
Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026
Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial pharminent May 12, 2026
Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis pharminent May 12, 2026
Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS pharminent May 5, 2026
Clinical Data Celcuity strengthens case for ASCO-spotlighted breast cancer drug pharminent May 4, 2026
